|
Jun 24
|
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
|
|
Jun 21
|
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
|
|
May 15
|
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
|
|
May 15
|
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|
|
May 14
|
US Equity Markets Close Higher Tuesday as Producer Prices Rise
|
|
May 14
|
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
|
|
May 14
|
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
|
|
May 13
|
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
|
|
May 9
|
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
|
|
May 6
|
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
|
|
May 4
|
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 2
|
Ascendis Pharma Reports First Quarter 2024 Financial Results
|
|
Apr 25
|
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
|
|
Apr 24
|
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
|
|
Apr 24
|
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
|
|
Apr 2
|
Biotech With 520% Sales Growth Nears Next Buy Point
|
|
Mar 22
|
Two Health Care Stocks Outperform S&P 500, Offer Entries
|
|
Mar 22
|
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
|
|
Mar 22
|
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
|
|
Mar 22
|
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
|